4 results on '"Eliska Cechova"'
Search Results
2. Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q)
- Author
-
Monika Belickova, Anna Jonasova, Hana Votavova, Michaela Dostalova Merkerova, Jitka Vesela, Kyra Michalova, Zdenek Krejcik, Eliska Cechova, Zuzana Zemanova, Jaroslav Cermak, Miroslav Caniga, and R. Neuwirtova
- Subjects
Male ,Cancer Research ,Proto-Oncogene Proteins c-jun ,CD14 ,Interleukin-1beta ,Lipopolysaccharide Receptors ,Gene Expression ,CXCR4 ,Actin-Related Protein 2-3 Complex ,Monocytes ,Gene expression ,medicine ,Humans ,Stem Cell Niche ,Lenalidomide ,Aged ,business.industry ,Tumor Necrosis Factor-alpha ,Myelodysplastic syndromes ,Hematology ,Middle Aged ,medicine.disease ,Prognosis ,Thalidomide ,Up-Regulation ,Gene expression profiling ,Oncology ,ARPC1B Gene ,Case-Control Studies ,Myelodysplastic Syndromes ,Immunology ,Cancer research ,Chromosomes, Human, Pair 5 ,Tumor necrosis factor alpha ,Female ,Chromosome Deletion ,business ,Transcriptome ,medicine.drug ,Signal Transduction - Abstract
We used microarray profiling to investigate the direct effects of lenalidomide on gene expression in isolated CD14(+) monocytes from 6 patients with del(5q). Our data demonstrate that changes in genes involved the tumor necrosis factor (TNF) signaling pathway and the bone marrow stroma, suggesting that treatment with lenalidomide may help restore the damaged niche and suppress the TNF signaling pathway.Lenalidomide is an effective treatment for patients with del(5q) and myelodysplastic syndrome (MDS) The exact mechanism of lenalidomide function and its impact on the prognosis of patients is not known exactly.We used gene expression profiling to study the effect of lenalidomide therapy in peripheral blood CD14(+) monocytes of 6 patients with del(5q) and MDS.After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level. This change in gene expression, in conjunction with increased expression of repressed genes that affect the stem cell niche (ie, CXCR4 and CRTAP), may exert a positive effect on treated patients. In contrast, we found that increased expression of the ARPC1B gene may have a negative impact on the stability of patient remission.The observed changes in gene expression described here may contribute to the identification of pathways that are affected by lenalidomide, which may help to explain the effects of this drug.
- Published
- 2012
3. Changes in Gene Expression Profiles in Patients with 5q- Syndrome Caused by Lenalidomide Treatment
- Author
-
Anna Jonasova, Jaroslav Cermak, Monika Belickova, Michaela Dostalova Merkerova, Jitka Vesela, Zuzana Zemanova, Eliska Cechova, and Kyra Michalova
- Subjects
CD14 ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Molecular biology ,Cytokine ,Significance analysis of microarrays ,Gene expression ,TaqMan ,medicine ,Interleukin 8 ,Gene ,Lenalidomide ,medicine.drug - Abstract
Abstract 5023 A direct effects of lenalidomide on gene expression in 5q- patients was studied using HumanRef-8 v2 Expression BeadChips (Illumina). Expression profiles of 6 patients (before treatment and at the time of the first erytroid response) and 6 healthy controls were investigated from CD14+ monocytes of peripheral blood. Differentially expressed genes were identified by Significance Analysis of Microarrays (SAM). Simultaneously, selected genes (TNF, JUN, IL1) were monitored in the course of treatment using Real-Time PCR with Taqman Gene Expression Assays. A comparison of gene expression levels before and during lenalidomide treatment revealed 97 differentially expressed genes (FC >2; p To conclude, described changes in genes expression may contribute to identification of the pathways affected by lenalidomide and to the explanation of some effects of this drug that have not been fully understood yet. Supported by grants NS/9634 MZCR, UHKT2005 00023736, MSM0021620808 and COST EUGESMA Disclosures: No relevant conflicts of interest to declare.
- Published
- 2011
- Full Text
- View/download PDF
4. Early-life exposure to persistent organic pollutants (OCPs, PBDEs, PCBs, PFASs) and attention-deficit/hyperactivity disorder: A multi-pollutant analysis of a Norwegian birth cohort
- Author
-
Virissa Lenters, Nina Iszatt, Joan Forns, Eliška Čechová, Anton Kočan, Juliette Legler, Pim Leonards, Hein Stigum, and Merete Eggesbø
- Subjects
Environmental sciences ,GE1-350 - Abstract
Background: Numerous ubiquitous environmental chemicals are established or suspected neurotoxicants, and infants are exposed to a mixture of these during the critical period of brain maturation. However, evidence for associations with the risk of attention-deficit/hyperactivity disorder (ADHD) is sparse. We investigated early-life chemical exposures in relation to ADHD. Methods: We used a birth cohort of 2606 Norwegian mother–child pairs enrolled 2002–2009 (HUMIS), and studied a subset of 1199 pairs oversampled for child neurodevelopmental outcomes. Concentrations of 27 persistent organic pollutants (14 polychlorinated biphenyls, 5 organochlorine pesticides, 6 brominated flame retardants, and 2 perfluoroalkyl substances) were measured in breast milk, reflecting the child's early-life exposures. We estimated postnatal exposures in the first 2 years of life using a pharmacokinetic model. Fifty-five children had a clinical diagnosis of ADHD (hyperkinetic disorder) by 2016, at a median age of 13 years. We used elastic net penalized logistic regression models to identify associations while adjusting for co-exposure confounding, and subsequently used multivariable logistic regression models to obtain effect estimates for the selected exposures. Results: Breast milk concentrations of perfluorooctane sulfonate (PFOS) and β‑hexachlorocyclohexane (β-HCH) were associated with increased odds of ADHD: odds ratio (OR) = 1.77, 95% confidence interval (CI): 1.16, 2.72 and OR = 1.75, 95% CI: 1.22, 2.53, per interquartile range increase in ln-transformed concentrations, respectively. Stronger associations were observed among girls than boys for PFOS (pinteraction = 0.025). p,p′‑Dichlorodiphenyltrichloroethane (p,p′-DDT) levels were associated with lower odds of ADHD (OR = 0.64, 95% CI: 0.42, 0.97). Hexachlorobenzene (HCB) had a non-linear association with ADHD, with increasing risk in the low-level exposure range that switched to a decreasing risk at concentrations above 8 ng/g lipid. Postnatal exposures showed similar results, whereas effect estimates for other chemicals were weaker and imprecise. Conclusions: In a multi-pollutant analysis of four classes of chemicals, early-life exposure to β-HCH and PFOS was associated with increased risk of ADHD, with suggestion of sex-specific effects for PFOS. The unexpected inverse associations between p,p′-DDT and higher HCB levels and ADHD could be due to live birth bias; alternatively, results may be due to chance findings. Keywords: Attention-deficit/hyperactivity disorder (ADHD), Contaminants, Endocrine disrupting chemicals (EDCs), Environmental chemicals, Hyperkinetic disorder, Neurodevelopment
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.